Page 4 of Attachment D 
- 4 - 
In concluding these brief remarks, I wish to emphasize that the member 
firms of the PMA, which I represent as well as other industrial firms engaged 
in recombinant DNA activities, endorse all of the provisions of the NIH Guide- 
lines and to the best of my knowledge have voluntarily complied with them. Such 
compliance includes physical and biological containment, training of personnel, 
good laboratory practices, medical surveillance, the establishment of Institu- 
tional Biosafety Committees and all other factors necessary to assure the health 
and safety of persons engaged in research and/or production. We deem such 
and for that matter in our own best interest, 
compliance to be in the public interest/ We commend the National Institutes of 
Health for their foresight in devising the Guidelines to assure that the benefits 
to be derived are not impeded by unnecessary constraints in research and indus- 
trial applications of this technology. We also applaud the creation of this Sub- 
committee on Industrial Practices as a means for consideration of the special 
problems which may arise as commercial development of this technology be- 
comes a reality. I can provide you an assurance that the industrial sector is 
prepared to offer its expertise and assistance as you undertake the assignment 
given to you by the Federal Interagency Advisory Committee. 
[379] 
